EUVIMEDEUVIMED entdecken
Crossref

Lung‐Targeting Interleukin‐10 mRNA Sulfonium Lipid Nanoparticles Ameliorate Acute Lung Injury

Yuqin Men, David O Popoola iD, Yuqi Song iD, Zhi Cao, Robert Gardner, Rezwana Karim, Chunyan Wang, Nathan Tucker iD, Robert Cooney, Qinghe Meng iD, Yamin Li iD

Small · 20.11.2026

DOI: 10.1002/smll.76758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 20.11.2026. Verfasst von Yuqin Men und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York, USA. Die Arbeit nennt 88 Literaturangaben. Gefördert von: Francis Hendricks Endowment Fund, NIH grants, SUNY Upstate Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute respiratory distress syndrome (ARDS) is the most severe manifestation of acute lung injury (ALI), characterized by diffuse pulmonary inflammation, impaired gas exchange, and high morbidity and mortality. Despite the clinical significance of ARDS, no effective pharmacological therapies are currently available. In this study, we developed a lung‐targeted mRNA‐sulfonium lipid nanoparticle (mRNA/sLNP) delivery system for the treatment of ALI/ARDS in a mouse model. We first examined different heads and tails to optimize sulfonium lipid structure, leading to the identification of a top‐performing HOSEH formulation. HOSEH sLNP was comprehensively characterized and subsequently loaded with interleukin‐10 (IL‐10) mRNA, an immunomodulatory cytokine with potent anti‐inflammatory activity. As a proof‐of‐concept, in a lipopolysaccharide (LPS)‐induced ALI mouse model, IL‐10 mRNA/sLNP demonstrated both prophylactic and therapeutic efficacy, significantly attenuating pulmonary and systemic inflammation, restoring alveolar‐capillary barrier integrity, and reducing lung tissue damage. These findings highlight the potential of lung‐targeted mRNA therapeutics in inflammatory lung diseases. With further development, IL‐10 mRNA/sLNP may represent a promising strategy for the treatment of ALI and ARDS.

Schlagwörter

Stichwörter der Autor:innen

IL‐10acute lung injurylipid nanoparticlelung‐targetingmRNA delivery

Autor:innen und Institutionen

  • Department of Pharmacology, State University of New York, Upstate Medical University, Syracuse, New York, USA.
  • Department of Surgery, State University of New York, Upstate Medical University, Syracuse, New York, USA.
  • Sepsis Interdisciplinary Research Center (SIRC), State University of New York, Upstate Medical University, Syracuse, New York, USA.

ORCID-Profile: David O Popoola, Yuqi Song, Nathan Tucker, Qinghe Meng, Yamin Li

Förderung

  • Francis Hendricks Endowment Fund
  • NIH grants
  • SUNY Upstate Medical University
  • State University of New York Upstate Medical University

Zitieren

APA

Men, Y., Popoola, D. O., Song, Y., Cao, Z., Gardner, R., Karim, R., Wang, C., Tucker, N., Cooney, R., Meng, Q., & Li, Y. (2026). Lung‐Targeting Interleukin‐10 mRNA Sulfonium Lipid Nanoparticles Ameliorate Acute Lung Injury. Small. https://doi.org/10.1002/smll.76758

Vancouver

Men Y, Popoola DO, Song Y, Cao Z, Gardner R, Karim R, et al. Lung‐Targeting Interleukin‐10 mRNA Sulfonium Lipid Nanoparticles Ameliorate Acute Lung Injury. Small. 2026. doi:10.1002/smll.76758

BibTeX
@article{Men2026,
  author = {Men, Yuqin and Popoola, David O and Song, Yuqi and Cao, Zhi and Gardner, Robert and Karim, Rezwana and Wang, Chunyan and Tucker, Nathan and Cooney, Robert and Meng, Qinghe and Li, Yamin},
  title = {Lung‐Targeting Interleukin‐10 mRNA Sulfonium Lipid Nanoparticles Ameliorate Acute Lung Injury},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.76758}
}
Kostenlos starten →